Medinet will develop and commercialize Stempeucel in Japan, pending regulatory clearance, and receive an upfront payment with additional milestone and royalty if the Tokyo-listed firm exercises the option to license the product
Ratan Tata’s simultaneous chairmanship of Tata Sons and Tata Trusts offered coherence and continuity. The so-called cracks in the Trusts’ structure are signs of evolution, an enduring institution adapting to new norms of accountability and self-governance
Jayesh Logistics IPO | Investors have bid 71.29 lakh shares against the IPO size of 17.91 lakh shares via 1,221 applications.
Fractal joins the growing wave of firms seeking to go public in India on the heels of two IPOs this month that raised more than $1 billion each
The company, part of mining and metals conglomerate Vedanta Group, filed draft papers for the IPO in early October
In June, the firm raised Rs 125 crore in a pre-IPO placement from investors including HDFC Life, SBI Life, Akash Bhanshali and Jagdish Master, valuing the company at around Rs 1,625 crore
As per the processing status of draft offer documents, the SEBI has issued observations on IPO papers of Milky Mist Dairy Food, and Curefoods India on October 24, and Kanodia Cement on October 20.
As part of the agreement, the tech major will provide a suite of IT services, including core business applications, infrastructure operations, end-user support, software asset governance, and project execution.
In a freewheeling chat with Moneycontrol, Peyush Bansal, CEO and co-founder of the company said it doesn't matter to him what the total addressable market (TAM) is beyond a certain point. "I don't get into this, I don’t track it. I think this is an analyst’s job."
Apart from these three new IPOs, the October month, so far, has seen 10 IPOs including seven worth Rs 35,791-crore from the mainboard segment.
The Tamil Nadu-based dairy major is gearing up for a Dalal Street debut as it looks to strengthen its balance sheet, diversify beyond southern markets, and take on larger FMCG and dairy rivals like Amul, Hatsun Agro and Britannia.
Eyewear retailer posted a strong quarterly performance led by store expansion and international growth
Studds Accessories IPO | The public issue comprises of entirely offer-for-sale of 77.86 lakh shares by promoters and other selling shareholders.
Lenskart Solutions IPO | The company will raise Rs 2,150 crore via fresh shares, while promoters and investors will be offloading 12.75 crore equity shares via offer-for-sale.
While India's growth indicators remain strong, October's softer PMI and persistent trade uncertainties raise uncomfortable questions
In the short term, Eli Lilly and Novo Nordisk will continue to dominate due to strong branding and doctor trust. But in the medium to long term, expect Indian pharma to emerge as a major competitive force bringing innovation, affordability, and scale to one of the fastest-growing drug segments in history.
Due to pre-IPO rounds, the OFS or offer for sale portion may be trimmed and the final combined size of the issue may fall between Rs 7,250 crore ($826 mn) to Rs 7,350 crore ($837 mn), sources told Moneycontrol
“Semaglutide, denosumab and abatacept are the three molecules that will help us mitigate the impact of declining Revlimid sales and bring back growth momentum,” said M.V. Narasimham, Chief Financial Officer, in a post-earnings interview.
Aditya Birla Sun Life AMC's assets under management stood at Rs 4.25 lakh crore at the end of September 2025, a growth of 11 percent.
Lenskart proposes to utilise the proceeds from the IPO for various strategic initiatives, including capital expenditure for setting up new Company-operated Company-owned (CoCo) stores in India
Orkla India IPO | The public issue is entirely an offer-for-sale of 2.28 crore equity shares by promoter Orkla Asia Pacific, and other shareholders - Navas Meeran and Feroz Meeran.
Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro, launched earlier this year.
During the entire 2024-25 fiscal, Prefab Technologies had posted a net profit of Rs 59.32 crore, and a total income of Rs 1,140.49 crore.
The surge in profitability was underpinned by a 35% rise in revenues to ₹1,653 crore and a 136% jump in EBITDA to ₹429 crore, lifting margins to 26% from 14.9% a year earlier.
Four key priorities have been put in place by the new CEO & MD to drive growth, of which one can be disruptive in the short-term
